The utility of intravenous immunoglobulin infection prophylaxis in patients on anti-CD38 therapies
Journal of Oncology Pharmacy Practice
Published online on June 02, 2025
Abstract
Journal of Oncology Pharmacy Practice, Ahead of Print.
BackgroundAnti-CD38 directed therapies have emerged as targeted treatments for multiple myeloma (MM) and light chain (AL) amyloidosis. Intravenous immunoglobulin (IVIG) supplementation has been shown to reduce the risk of bacterial infections by 39% in ...
BackgroundAnti-CD38 directed therapies have emerged as targeted treatments for multiple myeloma (MM) and light chain (AL) amyloidosis. Intravenous immunoglobulin (IVIG) supplementation has been shown to reduce the risk of bacterial infections by 39% in ...